Avecho Biotechnology has moved a major step closer to completing its pivotal Phase 3 study of a TPM-enhanced cannabidiol capsule for insomnia after an independent Data Monitoring Board unanimously recommended that the trial continue with its originally planned enrolment of 519 participants.
Avecho interim review clears path to complete pivotal Phase 3 insomnia trial
June 24, 2026 Australian Biotech
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News

